Global Cord Blood Corporation (NYSE: CO) announced June 4, 2019, that its board of directors received a non-binding proposal letter from Cordlife Group Limited for the two companies to combine by way of a statutory merger. Under the terms of the nonbinding proposal, Cordlife will issue its ordinary shares at SGD0.5 per ordinary share, and in exchange, will receive all of the outstanding ordinary shares of Global Cord Blood Corporation (GCBC) at US$7.50 per share. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
RoosterBio and Tissue Regeneration Therapeutics Collaborate on Human Umbilical Cord-Derived MSC Bioprocess Systems
Collaboration commercializes biological tools to advance the companies’ shared goal of accelerating the field of Regenerative Medicine.
FREDERICK, Md., May 29, 2019 — RoosterBio Inc. and Tissue Regeneration Therapeutics Inc.(TRT) today announced a strategic collaboration to advance their shared goal of accelerating the development of the Regenerative Medicine field. This collaboration will productize TRT’s core technology around human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) to the entire Regenerative Medicine marketplace. This powerful set of biological tools will be made commercially available via integration into RoosterBio’s unique product formats for rapid incorporation into tomorrow’s Regenerative Medicine products. [Read more…]
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]
Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent
FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 62
- Next Page »